Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Market Closed 10-09 16:00:00 EDT

11.99

-0.04

-0.33%

盘后11.99

+0.000.00%

19:30 EDT

High12.29	Low11.90	Vol1.09M
Open11.98	D1 Closing12.03	Amplitude3.24%
Mkt Cap1.24B	Tradable Cap1.06B	Total Shares103.52M
T/O13.12M	T/O Rate1.23%	Tradable Shares88.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":11.99,"timestamp":1791576000000,"preClose":12.03,"halted":0,"volume":1086585,"hourTrading":{"tag":"盘后","latestPrice":11.99,"preClose":11.99,"latestTime":"19:30 EDT","volume":26792,"amount":321236.08,"timestamp":1791588604203,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003325020781379813,"floatShares":88686700,"shares":103517562,"eps":-1.351255,"marketStatus":"Market Closed","change":-0.04,"latestTime":"10-09 16:00:00 EDT","open":11.98,"high":12.29,"low":11.9,"amount":13122819.608369999,"amplitude":0.032419,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.351255,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":12.03,"preHourTrading":{"tag":"盘前","latestPrice":11.99,"preClose":12.03,"latestTime":"09:29 EDT","volume":227,"amount":2723.2078834999998,"timestamp":1791552599999,"change":-0.04,"changeRate":-0.003325,"amplitude":0.147963},"postHourTrading":{"tag":"盘后","latestPrice":11.99,"preClose":11.99,"latestTime":"19:30 EDT","volume":26792,"amount":321236.08,"timestamp":1791588604203,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6620725532837151,"impliedVol":1.1407,"impliedVolPercentile":0.5179},"requestUrl":"/m/hq/s/ORIC","defaultTab":"news","newsList":[{"id":"2673074817","title":"What ORIC Pharmaceuticals (ORIC)'s Cancer Research UK Partnership Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074817","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074817?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:36","pubTimestamp":1791455765,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals reported that Cancer Research UK has agreed to fully fund, sponsor, design and run early clinical development of ORIC-259, a potential first in class CIP2A targeted cancer therapy, with ORIC retaining an option to reacquire rights after Phase 1/2 data.\nThis collaboration shifts early development costs and execution risk for ORIC-259 to Cancer Research UK while preserving upside for ORIC Pharmaceuticals through future milestones and royalties.\nWe will now look at how ORIC...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/what-oric-pharmaceuticals-orics-cancer-research-uk-partnersh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/what-oric-pharmaceuticals-orics-cancer-research-uk-partnersh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673806343","title":"ORIC Pharmaceuticals (ORIC) Gains A De Risked Path As Undervalued Case Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673806343","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673806343?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:24","pubTimestamp":1791311050,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) drew fresh attention after partnering with Cancer Research UK to advance ORIC-259, a potential first in class CIP2A targeted cancer therapy, through fully funded early clinical development.\nAt a share price of $12.49, ORIC Pharmaceuticals has seen short term momentum soften, with a 7 day share price return down 6.58% and a 30 day move down 2.88%. This comes even as the 90 day gain of 14.59% and year to date share price return of 52.88% point to stronger underlying...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/oric-pharmaceuticals-oric-gains-a-de-risked-path-as-underval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/oric-pharmaceuticals-oric-gains-a-de-risked-path-as-underval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673052900","title":"Oric Pharmaceuticals participates in a conference call with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2673052900","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673052900?lang=en_us&edition=fundamental","pubTime":"2026-10-06 22:40","pubTimestamp":1791297610,"startTime":"0","endTime":"0","summary":"JPMorgan discusses Enozertinib, (formerly known as ORIC-114), with management on a conference call to be held on October 6 at 12 pm. Webcast Link P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-participates-in-a-conference-call-with-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-participates-in-a-conference-call-with-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UYG","IYG","LU1244550577.SGD","LU2237443549.SGD","IE000WAW04H5.SGD","PGF","IE00BJTD4N35.SGD","LU1116320901.HKD","IE00BLSP4239.USD","LU0868494708.USD","IYF","ORIC","IXG","LU2552382058.USD","FTXO","LU2106854487.HKD","IE00BKVL7J92.USD","LU0345770308.USD","LU0820562030.AUD","LU1670627923.USD","LU0689472784.USD","XLF","LU0859254822.USD","LU0882574139.USD","FNCL","LU1629891620.HKD","JPMO","LU0683600562.USD","LU2237443622.USD","LU2236285917.USD","LU2756315318.SGD","VFH","LU2211815571.USD","IE000M9KFDE8.USD","JPM","LU0496365809.HKD","BK4582","LU2592432038.USD","IE00BYXW3230.USD","KBWB","TFNS","TRUF","BK4534","BK4139","JPO","LU0203347892.USD","IE00BFXG1179.USD","LU1244550221.USD","LU2756315664.SGD","IE0034235303.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081107","title":"Oric Pharmaceuticals, - Retains Option to Reacquire Oric-259 Rights After Phase 1/2 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081107?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA5B3F3W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081104","title":"Oric® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class Cip2a-Targeted Therapy into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081104?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA5B3F3W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081765","title":"ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081765","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081765?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":"ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374985/0/en/oric-pharmaceuticals-announces-agreement-with-cancer-research-uk-to-advance-a-potential-first-in-class-cip2a-targeted-therapy-into-clinical-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043657","title":"Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043657?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:01","pubTimestamp":1791198091,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Inc (ORIC) has an average rating of buy and mean price target of $21.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709935","title":"Oric Pharmaceuticals, Inc. : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709935?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:04","pubTimestamp":1791194652,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672741439","title":"Oric Pharma Director Richard A. Heyman Disposes of Common Shares Worth $86,518.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2672741439","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672741439?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:51","pubTimestamp":1790977880,"startTime":"0","endTime":"0","summary":"Oric Pharma director Richard A. Heyman disposes of common shares worth $86,518.47Oric Pharmaceuticals director Richard A. Heyman exercised stock options for 3,500 shares at $1.6 on Oct. 1, 2026.He sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL3qdGxP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma Director Richard A. Heyman Disposes of Common Shares Worth $86,518.47","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672174968","title":"Oric Pharma Grants 161,550 Inducement Stock Options to New Hires Under 2022 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672174968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672174968?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:30","pubTimestamp":1790973021,"startTime":"0","endTime":"0","summary":"Oric Pharma grants 161,550 inducement stock options to new hires under 2022 planOric Pharmaceuticals granted 161,550 non-qualified stock options, 26,850 restricted stock units to six new non-executive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL7q3QNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BK4139","BCDF","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","IE00BQXX3F31.USD","BK4585","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672505749","title":"Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672505749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672505749?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:30","pubTimestamp":1790973000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nTUA6NJD5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672499177","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672499177","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672499177?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:30","pubTimestamp":1790973000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374038/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671280312","title":"Oric Pharma CFO Dominic Piscitelli Disposes of 13,400 Common Shares Worth $181,257.78","url":"https://stock-news.laohu8.com/highlight/detail?id=2671280312","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671280312?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:16","pubTimestamp":1790723809,"startTime":"0","endTime":"0","summary":"Oric Pharma CFO Dominic Piscitelli disposes of 13,400 common shares worth $181,257.78Oric Pharmaceuticals CFO Dominic Piscitelli exercised stock options for 13,400 common shares at USD 4.36 on Sept. 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4XFqWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma CFO Dominic Piscitelli Disposes of 13,400 Common Shares Worth $181,257.78","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669107196","title":"BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2669107196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669107196?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:31","pubTimestamp":1790159462,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) has an average rating of buy and mean price target of $20.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351366","title":"Oric Pharma Grants 39,200 Stock Options, 6,400 RSUs to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351366","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351366?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:30","pubTimestamp":1788553815,"startTime":"0","endTime":"0","summary":"Oric Pharma grants 39,200 stock options, 6,400 RSUs to new employees under inducement planOric Pharmaceuticals granted 39,200 non-qualified stock options, 6,400 restricted stock units to two new non-e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLv5KGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","BK4112","ORIC","IE00BQXX3D17.EUR","BK4139","IE00BQXX3F31.USD","LU2095319765.USD","NDAQ","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351352","title":"Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351352?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:30","pubTimestamp":1788553800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA8ZVGDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351489","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351489","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351489?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:30","pubTimestamp":1788553800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.  04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356805/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664280587","title":"Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664280587","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664280587?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:32","pubTimestamp":1788453158,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY), Oric Pharmaceuticals Inc ($ORIC) announced an update on their ongoing clinical study. Himalayas-1 pushes Bayer AG (BAYRY) and Or...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/himalayas-1-bayer-and-oric-double-down-on-prostate-cancer-with-new-phase-3-combo-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/himalayas-1-bayer-and-oric-double-down-on-prostate-cancer-with-new-phase-3-combo-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BAYRY","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664284940","title":"ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664284940","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664284940?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:05","pubTimestamp":1788379500,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.  02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355484/0/en/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663134160","title":"Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663134160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663134160?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:12","pubTimestamp":1787947941,"startTime":"0","endTime":"0","summary":"Oric Pharma CFO Dominic Piscitelli disposes of 77,000 common shares worth $1.05 millionOric Pharmaceuticals CFO Dominic Piscitelli sold 77,000 common shares on Aug. 26 at USD 13.69.He exercised stock ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLnCNhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.0176},{"period":"1month","weight":-0.0408},{"period":"3month","weight":0.1051},{"period":"6month","weight":0.1813},{"period":"1year","weight":-0.1484},{"period":"ytd","weight":0.4658}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.047029},{"month":6,"riseRate":0.714286,"avgChangeRate":0.161131},{"month":7,"riseRate":0.428571,"avgChangeRate":0.002728},{"month":8,"riseRate":0.714286,"avgChangeRate":0.102485},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.036648},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.08521},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}